TY - JOUR
T1 - Application of extracellular vesicles derived from mesenchymal stem cells as potential therapeutic tools in autoimmune and rheumatic diseases
AU - Huldani, Huldani
AU - Abdalkareem Jasim, Saade
AU - Olegovich Bokov, Dmitry
AU - Kamal Abdelbasset, Walid
AU - Nader Shalaby, Mohammed
AU - Thangavelu, Lakshmi
AU - Margiana, Ria
AU - Qasim, Maytham T.
N1 - Funding Information:
Not applicable.
Publisher Copyright:
© 2022
PY - 2022/5
Y1 - 2022/5
N2 - Mesenchymal stem cells (MSCs) have been proven to have superior potential to be used as therapeutic candidates in various disorders. Nevertheless, the clinical application of these cells have been restricted because of their tumorigenic properties. Increasing evidence has established that the valuable impacts of MSCs are mainly attributable to the paracrine factors including extracellular vesicles (EVs). EVs are nanosized double-layer phospholipid membrane vesicles contain various proteins, lipids and miRNAs which mediate cell‐to‐cell communications. Due to their inferior immunogenicity and tumorigenicity, as well as easier management, EVs have drawn attention as potential cell-free replacement therapy to MSCs. For that reason, herein, we reviewed the recent findings of researches on different MSC-EVs and their effectiveness in the treatment of several autoimmune and rheumatic diseases including multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, osteoporosis, and systemic lupus erythematosus as well as Sjogren's syndrome, systemic sclerosis and other autoimmune diseases.
AB - Mesenchymal stem cells (MSCs) have been proven to have superior potential to be used as therapeutic candidates in various disorders. Nevertheless, the clinical application of these cells have been restricted because of their tumorigenic properties. Increasing evidence has established that the valuable impacts of MSCs are mainly attributable to the paracrine factors including extracellular vesicles (EVs). EVs are nanosized double-layer phospholipid membrane vesicles contain various proteins, lipids and miRNAs which mediate cell‐to‐cell communications. Due to their inferior immunogenicity and tumorigenicity, as well as easier management, EVs have drawn attention as potential cell-free replacement therapy to MSCs. For that reason, herein, we reviewed the recent findings of researches on different MSC-EVs and their effectiveness in the treatment of several autoimmune and rheumatic diseases including multiple sclerosis, inflammatory bowel disease, rheumatoid arthritis, osteoarthritis, osteoporosis, and systemic lupus erythematosus as well as Sjogren's syndrome, systemic sclerosis and other autoimmune diseases.
KW - Autoimmune diseases
KW - Exosomes
KW - Mesenchymal stromal cells
KW - Microvesicles
KW - Rheumatic diseases
UR - http://www.scopus.com/inward/record.url?scp=85124838386&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2022.108634
DO - 10.1016/j.intimp.2022.108634
M3 - Review article
AN - SCOPUS:85124838386
SN - 1567-5769
VL - 106
JO - International Immunopharmacology
JF - International Immunopharmacology
M1 - 108634
ER -